Investigators from University of Pittsburgh have successfully prevented the onset of type 1 diabetes in mice prone to developing the disease using an antibody against a receptor on the surface of immune T-cells. // This study being published in the January issue of the journal Diabetes, have significant implications for the prevention of type 1 diabetes.
More than 700,000 Americans have type 1 diabetes, an autoimmune disorder in which the body errantly attacks the insulin-producing cells of the pancreas, causing chronically elevated levels of sugar in the blood, leading to blindness, kidney failure, heart disease and nerve damage. Previously known as juvenile diabetes, type 1 diabetes is usually diagnosed at a very early age, but in some cases it can be diagnosed in adulthood.
In this study, the Pitt researchers treated non-obese diabetic (NOD) mice with an antibody - a type of protein produced by the immune system that recognizes and helps fight infections and other foreign substances in the body - directed against a receptor known as CD137 on the surface of a type of immune cell called T-cells. Treating NOD mice with the anti-CD137 antibodies significantly suppressed the development of diabetes, whereas most of the control mice developed diabetes by the time they were six months old.
Interestingly, the antibody therapy did not appear to cure the NOD mice because the researchers were still able to see lymphocytes in their pancreatic islets, a tell-tale sign of pancreatic inflammation and autoimmunity. In addition, when the researchers isolated cells from the spleens of the antibody-treated mice and injected these cells into immune-deficient NOD mice, seven of the nine recipient mice developed type 1 diabetes, indicating that the donor mice still harbored pathogenic T-cells. On the other hand, when the researchers transferred a certain subset of T-cells from anti-CD137-treated mice that expressed two other receptors known as CD4 and CPage: 1 2 Related medicine news :1
. Human Antibody That Can Block SARS2
. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs3
. Cuba Registers New Antibody4
. Single Sugar Enables Antibody to Treat Inflammation5
. Monoclonal Antibody based system for Anthrax detection6
. Monoclonal Antibody Reduces Exacerbations in Asthmatics7
. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels8
. New Antibody for EGFR Causes Lung Cancer Regression9
. J591- an Antibody Exclusively Targets Tumors10
. Cancer Doctors Okays Controversial Prostate Therapy11
. Consensus on "Combination Therapy" for Breast Cancer